The amended charter also lifts total authorized capital stock to 395,000,000 shares. Holders also approved a revised 2015 Stock Incentive Plan that removes its evergreen provision.
The company expects costs of $55.0 million to $70.0 million for the discontinuation and $14.0 million to $18.0 million for the workforce reduction. It now sees cash lasting into the second quarter of 2027.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $181.8 million, plus short-term investments of $29.8 million, $211.6 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Editas Medicine
What is the ticker symbol of Editas Medicine?
Editas Medicine, Inc. trades under the ticker EDIT on NASDAQ.
Where is Editas Medicine listed?
Editas Medicine, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:8EM; LS:A2AC4K; LSE:0IFK; LSX:A2AC4K.
What is the SEC CIK of Editas Medicine?
The SEC Central Index Key (CIK) for Editas Medicine, Inc. is 1650664. Its filings are on SEC EDGAR.
How many shares does Editas Medicine have outstanding?
153,580,035 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05.
Which country or territory is Editas Medicine listed under?
Our directory records Editas Medicine, Inc. under United States.
What does Editas Medicine do?
Our directory classifies Editas Medicine, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Editas Medicine?
The ISIN recorded for Editas Medicine, Inc. is US28106W1036.
Does aibio.space cover Editas Medicine?
aibio.space lists Editas Medicine, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Editas Medicine incorporated?
SEC records list its state or country of incorporation as DE.
Is Editas Medicine profitable?
Editas Medicine, Inc. reported a net loss of $160.1 million for the fiscal year ended Dec 31, 2025, and used $165.2 million of cash in operations, per its annual report to the SEC.
How much does Editas Medicine spend on research and development?
$90.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Editas Medicine have?
$211.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Editas Medicine (EDIT) stock news?
Our latest story on Editas Medicine, dated Jun 2, 2025: "Editas Medicine holders approve doubling authorized common stock to 390,000,000". The amended charter also lifts total authorized capital stock to 395,000,000 shares. Holders also approved a revised 2015 Stock Incentive Plan that removes its evergreen provision. Source.
How long will Editas Medicine's cash last?
From our story of Dec 12, 2024: The company says it is acting to extend its cash runway and refocus resources on in vivo pipeline development. Source.
Is Editas Medicine in financial distress?
Our latest distress story, dated Dec 12, 2024: "Editas Medicine ends reni-cel program, cuts about 180 positions (65% of workforce)". The company expects costs of $55.0 million to $70.0 million for the discontinuation and $14.0 million to $18.0 million for the workforce reduction. It now sees cash lasting into the second quarter of 2027. Source.
Investor discussion: Editas Medicine
Members talk about Editas Medicine (EDIT). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Editas Medicine, newest first. Each line links the filing it comes from.
Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). Source
Distress
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,7.01,8.01,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:EDIT on TradingView.
SEC filings and registration
SEC name
Editas Medicine, Inc.
CIK
1650664
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
EDIT (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
11 HURLEY ST., CAMBRIDGE, MA, 02141
Phone
617-401-9000
Shares outstanding
153,580,035 as of 2026-07-31 (10-Q filed 2026-08-05)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Editas Medicine, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker EDIT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio